David M Rubin1, Chris Feudtner, Russell Localio, David S Mandell. 1. Division of General Pediatrics, Children's Hospital of Philadelphia, PolicyLab, Center to Bridge Research, Practice, and Policy,Safe Place, Philadelphia, Pennsylvania 19104, USA. rubin@email.chop.edu
Abstract
OBJECTIVE: The objective of this study was to compare on a national cohort of children with autism spectrum disorder (ASD) the concurrent use of >or=3 psychotropic medications between children in foster care and children who have disabilities and receive Supplemental Security Income, and to describe variation among states in the use of these medications by children in foster care. METHODS: Studied was the concurrent use of >or=3 classes of psychotropic medications, identified from the 2001 Medicaid claims of 43406 children who were aged 3 to 18 years and had >or=1 annual claim for ASD. Medicaid enrollment as a child in foster care versus a child with disabilities was compared. Multilevel logistic regression, clustered at the state level and controlling for demographics and comorbidities, yielded standardized (adjusted) estimates of concurrent use of >or=3 medications and estimated variation in medication use within states that exceeded 1 and 2 SDs from the average across states. RESULTS: Among children in foster care, 20.8% used >or=3 classes of medication concurrently, compared with 10.1% of children who were classified as having a disability. Differences grew in relationship to overall use of medications within a state; for every 5% increase in concurrent use of >or=3 medication classes by a state's population with disabilities, such use by children in a state's foster care population increased by 8.3%. Forty-three percent (22) of states were >1 SD from the adjusted mean for children who were using >or=3 medications concurrently, and 14% (7) of the states exceeded 2 SDs. CONCLUSIONS: Among children with ASD, children in foster care were more likely to use >or=3 medications concurrently than children with disabilities. State-level differences underscore policy or programmatic differences that might affect the receipt of medications in this population.
OBJECTIVE: The objective of this study was to compare on a national cohort of children with autism spectrum disorder (ASD) the concurrent use of >or=3 psychotropic medications between children in foster care and children who have disabilities and receive Supplemental Security Income, and to describe variation among states in the use of these medications by children in foster care. METHODS: Studied was the concurrent use of >or=3 classes of psychotropic medications, identified from the 2001 Medicaid claims of 43406 children who were aged 3 to 18 years and had >or=1 annual claim for ASD. Medicaid enrollment as a child in foster care versus a child with disabilities was compared. Multilevel logistic regression, clustered at the state level and controlling for demographics and comorbidities, yielded standardized (adjusted) estimates of concurrent use of >or=3 medications and estimated variation in medication use within states that exceeded 1 and 2 SDs from the average across states. RESULTS: Among children in foster care, 20.8% used >or=3 classes of medication concurrently, compared with 10.1% of children who were classified as having a disability. Differences grew in relationship to overall use of medications within a state; for every 5% increase in concurrent use of >or=3 medication classes by a state's population with disabilities, such use by children in a state's foster care population increased by 8.3%. Forty-three percent (22) of states were >1 SD from the adjusted mean for children who were using >or=3 medications concurrently, and 14% (7) of the states exceeded 2 SDs. CONCLUSIONS: Among children with ASD, children in foster care were more likely to use >or=3 medications concurrently than children with disabilities. State-level differences underscore policy or programmatic differences that might affect the receipt of medications in this population.
Authors: Alfiee M Breland-Noble; Eric B Elbogen; Elizabeth M Z Farmer; Melanie S Dubs; H Ryan Wagner; Barbara J Burns Journal: Psychiatr Serv Date: 2004-06 Impact factor: 3.084
Authors: Barbara J Burns; Susan D Phillips; H Ryan Wagner; Richard P Barth; David J Kolko; Yvonne Campbell; John Landsverk Journal: J Am Acad Child Adolesc Psychiatry Date: 2004-08 Impact factor: 8.829
Authors: Cynthia A Fontanella; Lynn A Warner; Gary S Phillips; Jeffrey A Bridge; John V Campo Journal: Psychiatr Serv Date: 2014-10-31 Impact factor: 3.084
Authors: Stephanie L Mayne; Michelle E Ross; Lihai Song; Banita McCarn; Jennifer Steffes; Weiwei Liu; Benyamin Margolis; Romuladus Azuine; Edward Gotlieb; Robert W Grundmeier; Laurel K Leslie; Russell Localio; Richard Wasserman; Alexander G Fiks Journal: Pediatrics Date: 2016-04-01 Impact factor: 7.124
Authors: Susan Dosreis; Yesel Yoon; David M Rubin; Mark A Riddle; Elizabeth Noll; Aileen Rothbard Journal: Pediatrics Date: 2011-11-21 Impact factor: 7.124
Authors: Roger S Akins; Paula Krakowiak; Kathleen Angkustsiri; Irva Hertz-Picciotto; Robin L Hansen Journal: J Dev Behav Pediatr Date: 2014-01 Impact factor: 2.225
Authors: Sarah L Logan; Joyce S Nicholas; Laura A Carpenter; Lydia B King; Elizabeth Garrett-Mayer; Jane M Charles Journal: Ann Epidemiol Date: 2012-01 Impact factor: 3.797
Authors: Scott D Grosse; Phyllis Nichols; Kwame Nyarko; Matthew Maenner; Melissa L Danielson; Lindsay Shea Journal: J Autism Dev Disord Date: 2021-09-28
Authors: Sarah L Logan; Laura Carpenter; R Scott Leslie; Elizabeth Garrett-Mayer; Kelly J Hunt; Jane Charles; Joyce S Nicholas Journal: J Child Adolesc Psychopharmacol Date: 2015-04-28 Impact factor: 2.576
Authors: Johnny Downs; Matthew Hotopf; Tamsin Ford; Emily Simonoff; Richard G Jackson; Hitesh Shetty; Robert Stewart; Richard D Hayes Journal: Eur Child Adolesc Psychiatry Date: 2015-10-15 Impact factor: 4.785
Authors: Paul M Bakaki; Alexis Horace; Neal Dawson; Almut Winterstein; Jennifer Waldron; Jennifer Staley; Elia M Pestana Knight; Sharon B Meropol; Rujia Liu; Hannah Johnson; Negar Golchin; James A Feinstein; Shari D Bolen; Lawrence C Kleinman Journal: PLoS One Date: 2018-11-29 Impact factor: 3.240